Literature DB >> 26279989

Purinergic signaling and human immunodeficiency virus/acquired immune deficiency syndrome: From viral entry to therapy.

Daniela F Passos1, Maria Rosa C Schetinger1, Daniela Br Leal1.   

Abstract

Human immunodeficiency virus (HIV) infection is a serious condition associated to severe immune dysfunction and immunodeficiency. Mechanisms involved in HIV-associated immune activation, inflammation and loss of CD4+ T cells have been extensively studied, including those concerning purinergic signaling pathways. Purinergic signaling components are involved in viral entry and replication and disease progression. Research involving the participation of purinergic signaling in HIV infection has been not only important to elucidate disease mechanisms but also to introduce new approaches to therapy. The involvement of purinergic signaling in the pathogenesis of HIV infection and its implications in the control of the HIV infection are reviewed in this paper.

Entities:  

Keywords:  Human immunodeficiency virus; Immune activation; Inflammation; Purinergic signaling

Year:  2015        PMID: 26279989      PMCID: PMC4534819          DOI: 10.5501/wjv.v4.i3.285

Source DB:  PubMed          Journal:  World J Virol        ISSN: 2220-3249


  87 in total

1.  Use of ATP analogs to inhibit HIV-1 transcription.

Authors:  Aarthi Narayanan; Gavin Sampey; Rachel Van Duyne; Irene Guendel; Kylene Kehn-Hall; Jessica Roman; Robert Currer; Hervé Galons; Nassima Oumata; Benoît Joseph; Laurent Meijer; Massimo Caputi; Sergei Nekhai; Fatah Kashanchi
Journal:  Virology       Date:  2012-07-06       Impact factor: 3.616

Review 2.  Pathophysiology and therapeutic potential of purinergic signaling.

Authors:  Geoffrey Burnstock
Journal:  Pharmacol Rev       Date:  2006-03       Impact factor: 25.468

3.  Editorial: Pannexin-1--the hidden gatekeeper for HIV-1.

Authors:  Audrey Paoletti; Syed Qasim Raza; Laurent Voisin; Frédéric Law; Marina Caillet; Isabelle Martins; Eric Deutsch; Jean-Luc Perfettini
Journal:  J Leukoc Biol       Date:  2013-09       Impact factor: 4.962

Review 4.  NTPDase and 5'-nucleotidase activities in physiological and disease conditions: new perspectives for human health.

Authors:  Maria Rosa C Schetinger; Vera Maria Morsch; Carla Denise Bonan; Angela T S Wyse
Journal:  Biofactors       Date:  2007       Impact factor: 6.113

Review 5.  Purinergic signalling: from normal behaviour to pathological brain function.

Authors:  Geoffrey Burnstock; Ute Krügel; Maria P Abbracchio; Peter Illes
Journal:  Prog Neurobiol       Date:  2011-09-01       Impact factor: 11.685

6.  Cell death by pyroptosis drives CD4 T-cell depletion in HIV-1 infection.

Authors:  Gilad Doitsh; Nicole L K Galloway; Xin Geng; Zhiyuan Yang; Kathryn M Monroe; Orlando Zepeda; Peter W Hunt; Hiroyu Hatano; Stefanie Sowinski; Isa Muñoz-Arias; Warner C Greene
Journal:  Nature       Date:  2014-01-23       Impact factor: 49.962

Review 7.  Nucleotide- and nucleoside-converting ectoenzymes: Important modulators of purinergic signalling cascade.

Authors:  Gennady G Yegutkin
Journal:  Biochim Biophys Acta       Date:  2008-02-12

Review 8.  CD73 and adenosine generation in the creation of regulatory microenvironments.

Authors:  F S Regateiro; S P Cobbold; H Waldmann
Journal:  Clin Exp Immunol       Date:  2013-01       Impact factor: 4.330

9.  The therapeutic potential of adenosine triphosphate as an immune modulator in the treatment of HIV/AIDS: a combination approach with HAART.

Authors:  Marc C E Wagner
Journal:  Curr HIV Res       Date:  2011-06       Impact factor: 1.581

10.  ATP release and purinergic signaling in NLRP3 inflammasome activation.

Authors:  Aurélie Gombault; Ludivine Baron; Isabelle Couillin
Journal:  Front Immunol       Date:  2013-01-08       Impact factor: 7.561

View more
  1 in total

Review 1.  The Potential of Purinergic Signaling to Thwart Viruses Including SARS-CoV-2.

Authors:  Davide Ferrari; Michele Rubini; Jorge S Burns
Journal:  Front Immunol       Date:  2022-06-17       Impact factor: 8.786

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.